Stockscreener 앱 받기
6.25
2.80%
0.17
전일 마감가:
$6.08
열려 있는:
$6.14
하루 거래량:
85,722
Relative Volume:
0.97
시가총액:
$606.43M
수익:
$117.05M
순이익/손실:
$-3.71M
주가수익비율:
-80.23
EPS:
-0.0779
순현금흐름:
$1.67M
1주 성능:
+3.14%
1개월 성능:
-2.95%
6개월 성능:
-14.97%
1년 성능:
-24.97%
1일 변동 폭
$6.07
$6.35
1주일 범위
$5.74
$6.35
52주 변동 폭
$5.44
$9.42
Gyre Therapeutics Inc Stock (GYRE) Company Profile
명칭
Gyre Therapeutics Inc
전화
(858) 284-0115
주소
12730 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
6.25 | 606.43M | 117.05M | -3.71M | 1.67M | -0.0779 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | Jefferies | Buy |
| 2025-08-26 | 개시 | H.C. Wainwright | Buy |
| 2025-03-11 | 개시 | Noble Capital Markets | Outperform |
| 2021-04-29 | 재개 | Stephens | Overweight |
| 2021-02-10 | 개시 | Piper Sandler | Overweight |
| 2020-05-21 | 개시 | Raymond James | Outperform |
| 2019-01-04 | 개시 | Oppenheimer | Outperform |
| 2018-02-12 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 재확인 | Chardan Capital Markets | Buy |
| 2017-12-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 개시 | Chardan Capital Markets | Buy |
| 2017-06-06 | 개시 | Ladenburg Thalmann | Buy |
| 2016-06-30 | 개시 | Rodman & Renshaw | Buy |
모두보기
Gyre Therapeutics Inc 주식(GYRE)의 최신 뉴스
Gyre Therapeutics Inc (GYRE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gyre Therapeutics Inc (GYRE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gyre Therapeutics Inc (GYRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gyre Therapeutics Inc (GYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gyre Therapeutics Inc (GYRE) Institutional Confidence - TradingKey
Gyre Therapeutics Inc (GYRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Gyre Therapeutics Inc (GYRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gyre Therapeutics Inc (GYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Gyre Therapeutics Inc (GYRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Gyre Therapeutics stockholders approve all proposals at annual meeting - Investing.com
Gyre Therapeutics Shareholders Approve Directors and Governance Measures - TipRanks
Gyre Therapeutics (NASDAQ: GYRE) investors back directors, pay and Series B conversion - Stock Titan
Gyre COO Ye Weiguo sells $17,276 in company stock - Investing.com
Gyre COO Ye Weiguo sells $17,276 in company stock By Investing.com - Investing.com UK
Gyre Therapeutics (GYRE) COO sells 2,800 shares after exercising options - Stock Titan
GYRE Q1 2026 Earnings: EPS Surprises to the Upside, Revenue Not Reported, Stock SlipsForward EPS Estimate - newsline.com
Gyre Therapeutics COO Ye Weiguo sells $128,885 in stock - Investing.com UK
Gyre Therapeutics COO Ye Weiguo sells $128,885 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics, Inc. (GYRE) reports Q1 loss, lags revenue estimates - MSN
Gyre Therapeutics (GYRE) COO sells 20,918 shares after exercising options - Stock Titan
[Form 4] GYRE THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
CEO of Gyre Therapeutics (NASDAQ: GYRE) receives 120,000 stock options - Stock Titan
GYRE: All proposals passed with sufficient votes and no shareholder questions were raised - TradingView
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Trend Analysis - newsline.com
Gyre therapeutics COO Ye Weiguo sells $218,561 in stock By Investing.com - Investing.com Australia
Gyre therapeutics COO Ye Weiguo sells $218,561 in stock - Investing.com
GYRE (GYRE) COO exercises options, sells 34,976 shares but keeps 700,000 - Stock Titan
RLMD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Gyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy - The Globe and Mail
Gyre updates corporate presentation detailing pipeline, China strategy and regulatory progress - TradingView
Gyre Therapeutics (NASDAQ: GYRE) details F351 liver fibrosis data and degrader programs - Stock Titan
New strong sell stocks for May 27th - MSN
Gyre Therapeutics (GYRE) Gains Momentum: Price Nears Key Resistance at $6.21Equal Weight ETF - The Legal Advocate
Gyre Therapeutics (GYRE) Holds Steady at $5.74, Testing Key Support ZoneInside Day Breakout - The Legal Advocate
GYRE SEC FilingsGyre Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises AnalystsRevenue Guidance Range - The Legal Advocate
China regulator accepts Gyre’s liver fibrosis drug application By Investing.com - Investing.com Nigeria
Gyre Therapeutics (GYRE) Declines 3.1% as Stock Tests Key Support Near $5.45Gap Up Stocks - The Legal Advocate
US High Growth Tech Stocks To Watch - simplywall.st
Law firm investigates Gyre Therapeutics for possible securities law violations and breaches of fiduciary duty. - Pluang
Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm - TMX Newsfile
Gyre Therapeutics COO Ye Weiguo sells $45,680 in stock By Investing.com - Investing.com Nigeria
Gyre Therapeutics COO Ye Weiguo sells $45,680 in stock - Investing.com
COO of GYRE Therapeutics (NASDAQ: GYRE) sells shares after option exercises - Stock Titan
New Strong Sell Stocks for May 27th - Yahoo Finance
Gyre Therapeutics Inc. (GYRE) Edges Lower, Testing Key Support LevelsMedian Line - The Legal Advocate
GYRE Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive Surprise Amid Revenue AbsenceProfit Margin Analysis - The Legal Advocate
Gyre Therapeutics (GYRE) Falters: Testing Key Support After 1.94% DeclineDividend Growth Stocks - newsline.com
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre-Revenue Stage - Newser
Gyre therapeutics COO Ye Weiguo’s $136,653 stock sale By Investing.com - Investing.com India
Gyre therapeutics COO Ye Weiguo’s $136,653 stock sale - Investing.com
Gyre Therapeutics Inc (GYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):